Protagonist Q3 net loss of $33.2M, cash $583M; key readouts expected in Q4 2024 and Q1 2025

Protagonist Therapeutics, Inc

2024-Q3 EPS reported $2.22 revenue$263,795,000

Net loss of $33.2M ($0.54 per share) vs $34.1M loss in prior-year Q3.
Cash, equivalents and marketable securities $583.3M as of Sep 30, up from $341.6M at Dec 31, 2023.
License & collaboration revenue $4.7M from Takeda deal; $263.8M for nine months includes $255M upfront.
Top line results expected: JNJ-2113 Phase 3 psoriasis (ICONIC-LEAD/TOTAL) in Q4 2024; Phase 2b UC (ANTHEM) and rusfertide Phase 3 (VERIFY) in Q1 2025.
Anticipates nomination of oral IL-17 development candidate in Q4 2024; hepcidin and obesity candidates in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.